

Amendments to the Claims:

1. (Currently amended) A method of treatment of condylomata acuminata in humans, which comprises:  
applying Bacillus Calmette-Guerin (BCG) to the affected area ~~infection~~.
2. and 3. (Cancelled)
4. (Previously amended) The method of claim 1 which comprises applying BCG to external and intraurethral condylomata acuminata.
5. to 7. (Cancelled)
8. (Currently amended) The method of claim 1 which comprises applying BCG in about 1 to about 30 treatments to the affected area ~~of the infection~~ using an individual treatment dosage of from about 1 to about 500 mg of the BCG, wherein said applications are made at time intervals from about 1 to about 30 days where the ~~[[for]]~~ applications number more than one.
9. (Currently amended) The method of claim 1 which comprises performing ablative surgery to the affected area ~~of the infection~~ prior to said applying BCG.
10. (Original) The method of claim 9 wherein said ablative surgery is effected by laser
11. (Currently amended) The method of claim 1 which comprises formulating said BCG with a keratolytic agent for topical application to the affected area ~~infection~~, and then topically applying said BCG to the affected area ~~infection~~.
12. (Currently amended) The method of claim 11 which comprises formulating BCG with a keratolytic agent for adherent application to the affected area ~~infection~~, and then adherently applying said BCG to the affected area ~~infection~~.
13. (Currently amended) The method of claim 1 which comprises formulating said BCG with powdered salicylic acid as an adherent cream for application to the affected area ~~infection~~, and then adherently applying said BCG to the affected area ~~infection~~.

14. (Currently amended) The method of claim 13 which comprises formulating said BCG with said salicylic acid in an amount of about 0.1 to about 50 wt% of the resulting formulation prior to said applying BCG to the affected area infection.

15. (Currently amended) The method of claim 14 which comprises formulating said BCG said salicylic acid in an amount of about 1 to about 10 wt% of the resulting formulation prior to applying BCG to the affected area infection.

16. (Cancelled)

17. to 19. (Cancelled)

20. (Currently amended) A therapeutic [[The]] composition for the treatment of condylomata acuminata, comprising Bacillus Calmette-Guerin (BCG) formulated with a keratolytic agent for topical application to the affected area, of claim 16 wherein said keratolytic agent is powdered salicylic acid.

21. (Original) The composition of claim 20 wherein said salicylic acid is present in an amount of from about 0.1 to about 50 wt% of the composition.

22. (Previously amended) The composition of claim 21 wherein said salicylic acid is present in an amount of about 1 to about 10 wt% of the composition.

23. (Currently amended) A therapeutic [[The]] composition for the treatment of condylomata acuminata, comprising Bacillus Calmette-Guerin (BCG) formulated with a keratolytic agent for topical application to the affected area, of claim 16 which is formulated with a keratolytic agent as a cream for topical adherent application to the affected area infection.

24. and 25. (Cancelled)